Nil

[Loofydralb]

Nil

 

[laksaboy]

Innovation and creativity cannot thrive in a totalitarian shithole, arts or sciences it is the same.

Since it's too expensive to be a sweatshop factory hub here, the only reliable way they can grow the economy is spending on infrastructure. Building, demolishing, rebuilding, rinse and repeat.

Which is what you're seeing all around you now.

 

[Leongsam]

Innovation and creativity cannot thrive in a totalitarian shithole, arts or sciences it is the same.

Since it's too expensive to be a sweatshop factory hub here, the only reliable way they can grow the economy is spending on infrastructure. Building, demolishing, rebuilding, rinse and repeat.

Which is what you're seeing all around you now.

This formula for success depends upon a regular injection of a growth hormone called CECA.

 

[Loofydralb]

Nil

 

[batman1]

Red Dot got the best talents in the world ???

 

[dredd]

Isn't this a joke?

The billions poured into bio sciences, the thousands of graduates generated from the universities. The professors and PhDs brought in from all over the world. The Many industries and companies set up in Sg. The billions of research grant given out. The many many feel good stories about achievements in the media. The endless bragging by politicians of how they've steered Sg into an intelligent, thinking nation.

And you cannot even develop a vaccine that is after all administered under EUA? No testing regimen. No animal trials. No data. No responsibility, no liability. How difficult could that be?

Not even the traditional inactivated vaccine? Really?

This Covid exposes so many lies about Sg and its hype.

How difficult can it be? Sure lah, for a moron like you, everything is easy. I am willing to wager a bet you don't even know why you pee every morning.

Covid-19 vaccine by Arcturus and Singapore's Duke-NUS in phase 2 trials​

Arcturus Therapeutics chief executive Joseph Payne.PHOTO: ARCTURUS THERAPEUTICS

Cheryl Tan

• PUBLISHED
  AUG 21, 2021, 5:00 AM SGT

SINGAPORE - Three different Covid-19 messenger RNA vaccines which may have reduced side effects when administered are being developed with Singapore's involvement in their clinical trials.
Developed by United States-firm Arcturus Therapeutics, the three vaccine candidates can be given at a much lower dose than the mRNA vaccines now available - such as those by Pfizer and Moderna - because of the "self-amplifying" mRNA technology they use.
Each dose of the Arcturus vaccine contains five micrograms of vaccine, compared to 30 mcg in the Pfizer vaccine and 100 mcg in the Moderna vaccine.

The first vaccine, known as ARCT-021, targets the wildtype, or original Sars-CoV-2 virus, and was developed together with the Duke-NUS Medical School in Singapore. Local phase two trials, administered by SingHealth's Investigational Medicine Unit, are still ongoing.
The two newer vaccines - ARCT-154 and ARCT-165 - target the four variants of concern, Alpha, Beta, Gamma and Delta.
The local clinical trials will evaluate the vaccines' safety and immune response against the variants, and as possible booster shots for people who have received the Pfizer vaccines, said Associate Professor Jenny Low, the unit's deputy clinical and scientific director.

Arcturus' chief executive Joseph Payne told The Straits Times that while both vaccines have shown effectiveness against the variants when tested on primates, the ARCT-154 showed a stronger response to the Delta variant, while the ARCT-165 had a bias for the Beta variant.
The ARCT-154 vaccine is also undergoing clinical trials in Vietnam, in parallel with the trials conducted here. The trials here will also evaluate the vaccine as a booster jab. The data for both trials will be pooled in November, he added.
While conventional mRNA vaccines "teach" the cells to produce the Sars-CoV-2 viral spike protein to trigger an immune response in the body, the self-amplifying mRNA vaccine produces the protein at a lower level for a longer period of time - usually a couple of weeks, said Mr Payne.
The longer duration will generate the same neutralising antibody response in the body as well as help it develop a more robust T-cell response. T-cells are thought to confer long-lasting immunity to the virus and its variants.
In addition, having a lower dose also means that each dose carries fewer lipid nanoparticles that deliver the mRNA and an ingredient known as polyethylene glycol (PEG), which could sometimes trigger a rare allergic reaction known as anaphylaxis. This could potentially improve the vaccine's safety profile, he added.
Asked if the lower vaccine dose would mean a lower chance or incidence rate of myocarditis (heart inflammation), Mr Payne said this was a possibility.
But while myocarditis has not been seen in trials for Arcturus' vaccines so far, more robust data is needed, he said.

https://eb2.3lift.com/pass?tl_click...40&bcud=7960&sid=66552&ts=1631087712&cb=31475

 

[Loofydralb]

Nil

 

[eatshitndie]

local presstitute keeps talking about nus-duke-arcturus vaccine but tan ku ku. since aug 2020. every now and then a few updates. may be aug 2022 or may be aug 2023. will require up to 36.9k trial subjects to get past stage 3. by then another dominant variant will render vaccine candidate obsolete. must execute in months not in years to be successful with mrna product. (now even duke is abandoning nus; soon it will just be nus-arcturus; and not long later it will just be national up skirt left with the tab.) lol!

https://www.sammyboy.com/threads/stinkapore-and-the-pap-fucked-up-covid-vaccine-program.300328/

https://www.sammyboy.com/threads/what-has-become-of-s’pore’s-us-220-mil-investment-in-arcturus-therapeutics’-covid-19-vaccine.301252/#post-3338816

https://www.sammyboy.com/threads/bi...rna-vaccines-development.306199/#post-3418367

https://www.sammyboy.com/threads/chinese-says-china-vaccine-is-fucked-up.298918/#post-3311758

duke-nus prof ooi talked big about it last nov-10 that sg’s research team had “positive preliminary results from early stage trials”. they were teaming up with arcturus to get a single dose vaccine out by 1st quarter of 2021. so far no news nor progress reports. may have to wait longer as it will require tens of thousands of willing subjects to start mid-stage to late-stage trials.

https://www.sammyboy.com/threads/sg...buying-covid-19-vaccines.300327/#post-3328547

#2
Quotes:
"Ho Ching, the 67-year-old chief executive officer of Temasek Holdings, Ltd., the city-state’s biggest sovereign investment fund, was one of several people who played a central role in picking Arcturus to develop its ARCT-021 vaccine for use against the scourge."

"On December 28, 2020, Arcturus’s shares fell sharply on the announcement that while it did receive approval from the Singapore Health Science Authority to proceed with a phase-2 clinical study of its vaccine candidate, “the data seemed to be underwhelming,..."

Threw US$220 million at Arcturus Therapeutics, a company with a less-than-sterling reputation.
Guess who made the decision?
Now US$200 million down the drain.


Singapore’s Coronavirus Bet Stumbles
Expensive jab likely not ready before the third quarter

John Berthelsen 23 Feb 2021 2

The Singapore government, which last year was among Asia’s leaders in its efforts to combat the Covid-19 coronavirus, appears to have stumbled, after the Economic Development Board agreed to pay a San Diego-based biopharma company, Arcturus Therapeutics Holdings, Inc. US$220 million to develop a vaccine in conjunction with the Duke University-National University of Singapore Medical School. Financial analysts in the US have downgraded the Arcturus stock after some of its clinical studies were less than promising and the vaccine looks likely to be delayed.

Singapore earlier had ambitions to vaccinate all of its citizens at the same pace as Israel and the United Arab Emirates have done. It has been buying vaccines from other sources and delayed the start of a program to inoculate its 5.7 million residents. As of February 20, according to the Our World in Data website, it had only vaccinated 1.6 percent of residents, behind 17 other nations including Morocco, Bahrain, and Poland.

“Of 31 Covid-19 vaccine trials (by Arcturus), currently some at are Phase 2 and others are at Phase 3 out of 221 at the start,” said an infectious disease specialist who asked not to be named. “Many are not going to achieve the grade, so I am not surprised."

So far, the Singapore media appears to have been silent on the Arcturus troubles. According to US media, neutralizing antibodies in the tests for Arcturus were at lower levels than for rival vaccine candidates. Arcturus is hoping its vaccine will not require a booster shot, making it easier to administer than vaccines that require two doses.
Said a Singaporean epidemiological expert who also declined to be named, Phase 2 trials of the Arcturus vaccine are still ongoing and if successful, phase 3 trials may take place late this year. He added, "Since the world won't have complete vaccination, being ready in 2022 is still okay, but doing phase 3 trials have just become more challenging. The Arcturus vaccine is late, but there is no basis to label it a failure."

Ho Ching, the 67-year-old chief executive officer of Temasek Holdings, Ltd., the city-state’s biggest sovereign investment fund, was one of several people who played a central role in picking Arcturus to develop its ARCT-021 vaccine for use against the scourge. She said in a Facebook post on Feb. 22 that 40 vaccination centers are to be established by the end of April, each able to administer 2,000 shots a day. Fourteen centers are now up and running. So far, the disease has sickened almost 60,000 victims, the majority of them migrant workers, although it has taken the lives of only 29, testimony to the island’s health system.

Singapore has budgeted the equivalent of US$750 million for vaccines, with Arcturus Therapeutics tapped to lead the country’s effort to control the coronavirus. Health care workers, the elderly, and front-liners were to be first in a bid to vaccinate the entire population by the third quarter of the year, which, if successful, would still put Singapore ahead of other Southeast Asian countries.

According to the Ministry of Health on its website, “As vaccine supply will arrive in Singapore in batches over several months as manufacturers increase their production of vaccines, vaccination should start with groups who are at greater risk and hence most in need of Covid-19 vaccination, including healthcare workers and Covid-19 frontline workers, as well as vulnerable groups at greater risk of severe disease from COVID-19 infection, such as the elderly.

How much the Arcturus effort will be a part of that is unknown, since its Phase 3 trials appear likely to run into the third quarter of the year. On December 28, 2020, Arcturus’s shares fell sharply on the announcement that while it did receive approval from the Singapore Health Science Authority to proceed with a phase-2 clinical study of its vaccine candidate, “the data seemed to be underwhelming,” according to the CNBC business news channel. Analyst Edward Arce at the Wall Street firm HC Wainright downgraded the stock on concerns his firm had “lost confidence in the potential of ARCT-021 to provide meaningful protection from SARS-CoV-2 infection and Covid-19.”

While the latest dataset “does not completely impair single-shot ARCT-021,” Arce wrote, “which may provide protection against Covid-19 infection in Phase 3, the lack of SARS-CoV-2 neutralizing antibody (NAb) titers at or above levels seen in convalescent sera reduces our confidence that ARCT-021 will be able to achieve competitive levels of vaccine efficacy with single-shot dosing. … At a minimum, the question will be asked by the market and unanswered until Phase 3, thereby limiting near-term upside and justifying a Market Perform rating.”

Raymond James Financial, Inc. also downgraded the stock, which fell sharply by 52 percent to US$43.96 on news of the downgrades before recovering on February 22 to US$59.59, well below the consensus target at US$106.15.

Arcturus announced its agreement with Singapore’s EDB to begin the development process in November, noting the provision of an upfront limited-recourse loan of US$45 million and terms for up to US$175 million to be used for the purchase of equipment, materials, and services related to the manufacture of the vaccine. Under the terms of the agreement, the loan is to be repaid through royalties on future ARCT-021 commercial sales.

However, if ARCT-021 doesn’t obtain regulatory approval, the pact contains a provision that the loan will be forgiven and Arcturus gets to keep the money. Additionally, Arcturus and the EDB have agreed to terms providing the EDB with the right to purchase up to US$175 million of ARCT-021 vaccine at pre-negotiated prices, with shipments expected to begin in the first quarter of 2021.

Arcturus has had a somewhat checkered corporate history. In March 2018, the company sued the chief executive officer, Joseph E. Payne, after pushing him out of his job a month earlier, citing “misconduct, poor judgment and bad decisions” during his tenure, accusing him in the lawsuit of self-dealing and conflicts of interest, and seeking damages. Among other charges, according to the suit, Payne attempted to transfer substantial amounts of Arcturus’s intellectual property to another firm, Providence Therapeutics, controlled by Payne’s personal friend and occasional business partner.

Payne, the company’s largest shareholder with 13.7 percent of the stock, fought back with the help of a group of allied shareholders, pushing out the board of directors and replacing the board with four directors he had recruited. According to a March 2018 statement from the company, an agreement was reached settling litigation between the two sides. Payne was quoted saying he was “extremely pleased” to be reinstated, bringing back his co-founder, Padmanabh Chivukula as chief scientific and chief operating officer, who had resigned after Payne was fired.

 

[eatshitndie]

How difficult can it be? Sure lah, for a moron like you, everything is easy. I am willing to wager a bet you don't even know why you pee every morning.

Covid-19 vaccine by Arcturus and Singapore's Duke-NUS in phase 2 trials​

Arcturus Therapeutics chief executive Joseph Payne.PHOTO: ARCTURUS THERAPEUTICS

Cheryl Tan

• PUBLISHED
  AUG 21, 2021, 5:00 AM SGT

SINGAPORE - Three different Covid-19 messenger RNA vaccines which may have reduced side effects when administered are being developed with Singapore's involvement in their clinical trials.
Developed by United States-firm Arcturus Therapeutics, the three vaccine candidates can be given at a much lower dose than the mRNA vaccines now available - such as those by Pfizer and Moderna - because of the "self-amplifying" mRNA technology they use.
Each dose of the Arcturus vaccine contains five micrograms of vaccine, compared to 30 mcg in the Pfizer vaccine and 100 mcg in the Moderna vaccine.

The first vaccine, known as ARCT-021, targets the wildtype, or original Sars-CoV-2 virus, and was developed together with the Duke-NUS Medical School in Singapore. Local phase two trials, administered by SingHealth's Investigational Medicine Unit, are still ongoing.
The two newer vaccines - ARCT-154 and ARCT-165 - target the four variants of concern, Alpha, Beta, Gamma and Delta.
The local clinical trials will evaluate the vaccines' safety and immune response against the variants, and as possible booster shots for people who have received the Pfizer vaccines, said Associate Professor Jenny Low, the unit's deputy clinical and scientific director.

Arcturus' chief executive Joseph Payne told The Straits Times that while both vaccines have shown effectiveness against the variants when tested on primates, the ARCT-154 showed a stronger response to the Delta variant, while the ARCT-165 had a bias for the Beta variant.
The ARCT-154 vaccine is also undergoing clinical trials in Vietnam, in parallel with the trials conducted here. The trials here will also evaluate the vaccine as a booster jab. The data for both trials will be pooled in November, he added.
While conventional mRNA vaccines "teach" the cells to produce the Sars-CoV-2 viral spike protein to trigger an immune response in the body, the self-amplifying mRNA vaccine produces the protein at a lower level for a longer period of time - usually a couple of weeks, said Mr Payne.
The longer duration will generate the same neutralising antibody response in the body as well as help it develop a more robust T-cell response. T-cells are thought to confer long-lasting immunity to the virus and its variants.
In addition, having a lower dose also means that each dose carries fewer lipid nanoparticles that deliver the mRNA and an ingredient known as polyethylene glycol (PEG), which could sometimes trigger a rare allergic reaction known as anaphylaxis. This could potentially improve the vaccine's safety profile, he added.
Asked if the lower vaccine dose would mean a lower chance or incidence rate of myocarditis (heart inflammation), Mr Payne said this was a possibility.
But while myocarditis has not been seen in trials for Arcturus' vaccines so far, more robust data is needed, he said.

https://eb2.3lift.com/pass?tl_click...40&bcud=7960&sid=66552&ts=1631087712&cb=31475

arcturus downgraded, and investors have remained silent or given up hope. only joseph payne talks up a good game. prof ooi at nus (no more duke-nus) doesn’t talk about it anymore. much frustration happening in that joint venture team. empress dowager still pushing for it (and throwing money at it). it’s edb’s venture and funds, not tummysick. as to why empress is “centrally” involved with edb’s venture, god knows. she has a finger in almost everything sinkie, and may be up your arse too.

 

[Loofydralb]

Nil

 

[Loofydralb]

Nil

 

[Loofydralb]

Nil

 

[Loofydralb]

Nil

 

[Loofydralb]

Nil

 

[Loofydralb]

Nil

 

[Loofydralb]

Nil

 

[Loofydralb]

Nil

 

[Loofydralb]

nil

 

[Loofydralb]

Nil

 

[eatshitndie]

There are no world class talent here. Period.

disagree. world crass upskirt and downblouse talents are all over in sg.